Replies to post #19039 on RespireRx Pharmaceuticals Inc (fka RSPI)

[jerrydylan]

http://stockcharts.com/h-sc/ui?s=COR&p=D&b=5&g=0&id=p88808768812&a=88732778 Money flow was strong on friday, nice reverse head and shoulders formation in the making. I think the DNA transaction is another example of both the US dollar weakness prompting consolidation from overseas but more importantly, a great innovator ( who also licenced a ton of it's technology from smaller biotechs) is off the radar and the money will have to go somewhere-both private investment capital and corporate R&D, though DNA will still hunt around for oncology R&D....i'D THINK.

[gfp927z]

Scstocks, OT - I've only had Level 2 for a few months, and it's been a big help. While I can see the bid and ask interest at each price level, just curious how you access the list of actual orders going in and out? I've seen others post a list of these actual orders here on I-hub, but so far haven't been able to locate/access these myself. Thanks for any pointers.

That's a good point about the proceeds from the Genentech acquisition. Mutual funds / bio index funds will need to reallocate the proceeds they receive back into other bios, with the larger names getting the bulk of it, though some could also flow down to into the mid/small caps.

[DewDiligence]

>…all of the fund money that was in genentec, will have to be redistributed among the remaining bio's, as roche is not considered a bio, hence the need for redistribution.<

That’s an overstatement because DNA is owned by index funds and general large-cap funds, not just biotech funds. Clearly, there will be a significant money-flow benefit to other biotechs, but I would guess that less than 50% of the investor money in DNA will flow into other biotechs.